Haematology 2018

First-line treatment options recommended by NCCN or ESMO 1,2

Median Follow up, mos (range)

Estimated 3- year PFS (%)

Symptomatic 1L FL 1,2

Phase 3 Study 3,4,5

N

Hiddemann, 2005 (GLSG) CHOP R-CHOP

18 (1–38) 18 (1–38)

205 223

50 75

NCCN only (2b) Alternative option*

Salles, 2011 (PRIMA)

36 (IQR 30–42) 36 (IQR 30–42)

513 505

R-chemo + observation R-chemo + R maintenance

58 75

R 2

R-CHOP

R-B

R-CVP

Hochster, 2009 (ECOG1496) CVP + observation CVP + R maintenance

44.4 44.4

113 115

33 64

Rituximab maintenance

1. Dreyling M, et al. Ann Oncol 2016; 27(Suppl. 5):v83–v90; 2. NCCN Guidelines. B-cell Lymphomas. Version 2.2017; 3. Jacobson CA, Freedman AS. Lancet 2013; 381:1163–1165;

*NCCN guideline recommendation only (category 2b); rituximab alone may be considered if low tumour burden 2 1L, first line;; chemo, chemotherapy CHOP, cyclophosphamide, vincristine, doxorubicin and prednisone/prednisolone; CVP, cyclophosphamide, vincristine and prednisone/prednisolone; FL, follicular lymphoma; PFS, progression-free survival; R, rituximab